— Long-term outcomes reinforce the high efficacy of Biktarvy® in people with HIV and HBV coinfection
— Investigational long-acting, twice-yearly treatment regimen of lenacapavir and broadly neutralizing antibodies (bNAbs) meets primary endpoint in Phase 2 study and gains Breakthrough Therapy Designation
— Late-breaker oral presentation of Phase 2 results from the first HIV cure clinical trial conducted in South Africa
Read the full company press release here.
Source : Gilead Sciences, Inc.
Related HIV and Co-Infections News
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.